AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Company changes name and prepares for HIV vaccine trial.
2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Research company Merix Bioscience announced the change of its name to Argos Therapeutics, Inc. Additionally, the company stated that it is preparing for an HIV clinical trial with Argos' proprietary RNA-loaded dendritic cell vaccine.
"This change in name reflects the evolution and success of our technology platform," said Clint Dederick, Jr., chairman and CEO of Argos Therapeutics. "With our patented technology, a clinical trial underway for renal cancer and a clinical trial scheduled to begin for HIV, we've entered into an exciting new chapter for our company. We're focused on providing new therapies that will offer patients around the globe a new promise for treating diseases, and a better quality of life during the treatment."
The company said that several events brought Argos to this juncture. In March 2004, Argos (then Merix) entered into an agreement with Geron in which Argos received 5 million shares of Geron stock, valued at over $43 million. In exchange, Geron was granted the co-exclusive right to use Argos' platform technology in specific therapeutic cancer vaccines using telomerase and other defined antigens. Argos' technology obtained significant validation when Geron announced that the telomerase cancer vaccine induced vigorous immune responses without side effects in a Phase I/II clinical trial recently completed at Duke University Medical Center.
Then, in June 2004, Argos and Kirin Brewery's Pharmaceutical Division entered into a collaboration to develop and commercialize dendritic cell vaccines in the areas of cancer, infectious diseases, autoimmune disorders and transplantation. As part of the agreement, Kirin made an equity investment in Argos and each party will contribute an estimated $45 to $65 million during the first three years of the collaboration.
Additionally, Argos began a clinical trial in the same month, focusing on the treatment of renal cancer. Results for this Phase I/II ...
- Merix Bioscience Changes its Name to Argos Therapeutics; Company Prepares for...
- Press release article from: Business Wire October 5, 2004 700+ words
...said Nicolette. "Argos has already generated an HIV vaccine and an investigator...Amsterdam. " The Argos vaccine is novel in...application covering its HIV vaccine technology. "Previously...We believe our Argos personalized RNA...
- Argos Therapeutics awarded NIH contract to further develop HIV immunotherapy...
- News wire article from: Chemical Business Newsbase October 27, 2006 700+ words
...Release) Argos Therapeutics (Argos) has been awarded a $21 M...immunotherapy candidates. Argos is developing personalized...disease. The contract, titled "HIV Vaccine Design and Development Teams...determine the immunogenicity of Argos' HIV immunotherapy candidate...
- AIDS Action Observes HIV Vaccine Awareness Day: Reason to Hope.
- Newspaper article from: AIDS Vaccine Week June 1, 2009 700+ words
...tragic reality, the ongoing search for an HIV vaccine gives us reason to hope. The HIV vaccine research field continues to advance, and...year of promise. Today, on May 18th, HIV Vaccine Awareness Day, AIDS Action urges everyone...
- HIV Vaccine Awareness Day Is May 18; Seattle Research Unit to Mark Day with...
- Press release article from: PR Newswire May 9, 2007 700+ words
...PRNewswire/ -- The Seattle HIV Vaccine Trials Unit, based at Fred Hutchinson...Clinton's challenge to develop an HIV vaccine to celebrate two new partners in its work to educate the community on HIV vaccine research. It will also dedicate...
- Wider participation required in HIV vaccine clinical trials/Une plus grande...
- Magazine article from: Weekly Epidemiological Record September 3, 2004 700+ words
...of women and adolescents is needed in HIV vaccine clinical trials, according to a group...experts, who attended a consultation on HIV vaccine trials in Lausanne, Switzerland, from...in particular, as well as race in HIV vaccine-related research and clinical trials...
- Experts offer mixed view of HIV vaccine's future.
- Newspaper article from: Hospice Management Advisor July 1, 2008 700+ words
Experts offer mixed view of HIV vaccine's future AIDS Healthcare Foundation...to stop funding research for the HIV vaccine and to put that money into prevention...repeated disappointments in the HIV vaccine research arena. None of the Phase...
- Many Americans Think an HIV/AIDS Vaccine Already Exists; May 18th Observance of...
- Press release article from: PR Newswire May 16, 2003 700+ words
...Hispanics (28 percent) believe that an HIV vaccine already exists and is being kept a secret...Institute is sponsoring the Sixth Annual HIV Vaccine Awareness Day on May 18. Communities...activities that will provide valuable HIV vaccine information to inform the public and...
- Science, social issues hamper development of HIV vaccine. (Duke University)
- Newspaper article from: AIDS Weekly May 31, 1993 700+ words
...knowledge is that "there is no preventive HIV vaccine on the near horizon with clear prospects...medicine who serves on several national HIV vaccine committees, said tough social and ethical...way to create a completely effective HIV vaccine is to have "unprecedented" cooperation...
- African Ministers review HIV vaccine development project.
- News wire article from: Asia Africa Intelligence Wire October 17, 2005 700+ words
...here Monday to review the status of HIV vaccine research and development, as well as...Programme being attended by some 200 HIV vaccine stakeholders, including African and...to be overcome in order to develop an HIV vaccine, Africa is currently facing the need...
- FACT SHEET: GLOBAL HIV VACCINE ENTERPRISE.
- News wire article from: The America's Intelligence Wire June 10, 2004 700+ words
...in endorsing the establishment of a Global HIV Vaccine Enterprise, a virtual consortium to accelerate HIV vaccine development. The President also announced plans to establish a second HIV Vaccine Research and Development Center in the U...
Source: HighBeam Research, Company changes name and prepares for HIV vaccine trial.